Summary of traditional and contemporary second-line regimens for relapsed or refractory classical Hodgkin lymphoma
| Regimen . | No. (overall) . | No. (%) transplanted . | % PET negative after second-line regimen . | PFS/EFS (transplanted patients*) . |
|---|---|---|---|---|
| ICE32 | 65 | 56 (86) | No PET CR: 26% by CT | 68% |
| DHAP39 | 102 | NR | No PET CR: 21% by CT | NR |
| IGEV40 | 91 | NR | 53.8% | NR |
| GVD41 | 91 (55 transplant naive) | 39 (71) | No PET CR: 19% by CT | 52% at 4 years |
| ESHAP42 | 82 | 75 (91) | 50% | Median PFS = 56 months |
| ICE → GVD (PET adapted, sequential)14 | 98 | 90 (92) | 77% (60% after ICE, additional 17% after GVD) | 78% @ 5 years† |
| BV → augICE (PET adapted, sequential)19 | 65 | 63 (97) | 83% (27% after BV, additional 56% after ICE) | 77% @ 5 years† |
| BV → ICE and others (PET adapted, sequential)43 | 56 | 50 (89) | 66% (43% after BV, additional 23 after additional salvage) | 67% @ 2 years |
| BV plus bendamustine20 | 55 | 40 (72) | 74% | 69.8% @ 2 years |
| BEGEV5 | 59 | 43 (73) | 75% | 77% @ 5 years |
| BV plus gemcitabine44 | 42 | 34 (76) | 67% | NR |
| BV plus ICE4 | 43 | 37 (86) | 74% | 80% @ 2 years |
| BV plus DHAP3 | 55 | 47 (85) | 81% | 74% @ 2 years (ITT population) |
| BV plus ESHAP45 | 66 | 60 (91) | 70% | 71% @ 30 months (ITT population) |
| BV-nivolumab21 | 91 | 67 (74) directly after BV-nivo 84 (92) altogether | 67% | 91% @ 3 years (for those transplanted directed after BV/nivo) 77% @ 3 years (ITT) |
| Pembrolizumab-GVD22 | 38 | 36 (95) | 95% | 96% @ 2 years† |
| Regimen . | No. (overall) . | No. (%) transplanted . | % PET negative after second-line regimen . | PFS/EFS (transplanted patients*) . |
|---|---|---|---|---|
| ICE32 | 65 | 56 (86) | No PET CR: 26% by CT | 68% |
| DHAP39 | 102 | NR | No PET CR: 21% by CT | NR |
| IGEV40 | 91 | NR | 53.8% | NR |
| GVD41 | 91 (55 transplant naive) | 39 (71) | No PET CR: 19% by CT | 52% at 4 years |
| ESHAP42 | 82 | 75 (91) | 50% | Median PFS = 56 months |
| ICE → GVD (PET adapted, sequential)14 | 98 | 90 (92) | 77% (60% after ICE, additional 17% after GVD) | 78% @ 5 years† |
| BV → augICE (PET adapted, sequential)19 | 65 | 63 (97) | 83% (27% after BV, additional 56% after ICE) | 77% @ 5 years† |
| BV → ICE and others (PET adapted, sequential)43 | 56 | 50 (89) | 66% (43% after BV, additional 23 after additional salvage) | 67% @ 2 years |
| BV plus bendamustine20 | 55 | 40 (72) | 74% | 69.8% @ 2 years |
| BEGEV5 | 59 | 43 (73) | 75% | 77% @ 5 years |
| BV plus gemcitabine44 | 42 | 34 (76) | 67% | NR |
| BV plus ICE4 | 43 | 37 (86) | 74% | 80% @ 2 years |
| BV plus DHAP3 | 55 | 47 (85) | 81% | 74% @ 2 years (ITT population) |
| BV plus ESHAP45 | 66 | 60 (91) | 70% | 71% @ 30 months (ITT population) |
| BV-nivolumab21 | 91 | 67 (74) directly after BV-nivo 84 (92) altogether | 67% | 91% @ 3 years (for those transplanted directed after BV/nivo) 77% @ 3 years (ITT) |
| Pembrolizumab-GVD22 | 38 | 36 (95) | 95% | 96% @ 2 years† |
Except when IIT stated.
Updated since original publications.
BEGEV, bendamustine, gemcitabine, and vinorelbine; CT, computed tomography; DHAP, dexamethasone, cytarabine, and cisplatin; EFS, event-free survival; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; IGEV, ifosfamide, gemcitabine, vinorelbine, and prednisone; ITT, intent to treat; NR, not reported.